Skip to main content

Pharma/Regulatory

RheumNow Podcast square

Telemedicine Upside Interview with Dr. Alvin Wells

Dec 03, 2021

In spite of the transformative growth of telemedicine during the COVID-19 pandemic, rheumatologists use of telemedicine is waning, much like the use of masks. Dr. Jack Cush interviews telemedicine guru, Dr. Alvin Wells, on the current state of telemedicine and what the future holds for

Read Article
dementia,brain

Rheumatoid Arthritis, Dementia and Cognitive Dysfunction

Dec 02, 2021

Rheumatoid arthritis (RA) has been linked to a higher risk of dementia and cognitive dysfunction, but interestingly this association has diminished in the last few decades with aggressive DMARD and targeted therapies..



This makes sense when you see that dementia in RA is associated

Read Article
lung%2Cbright.jpg

Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles

Dec 01, 2021

Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter

Read Article
Sle.vote_.criteria.png

DORIS - Defining Remission in Lupus

Nov 29, 2021

Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE.  A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016. Now the 2021

Read Article
rachel.tate

Safety of Psoriatic Biologics in Pregnancy

Nov 24, 2021

Little is known about the safety of newer biologic use during pregnancy, especially in patients who either conceive while on a biologic or must remain on a biologic during pregnancy (often the case with IBD and inflammatory arthritis). A report from ACR 2021 (Abstract 1713) examined the risk

Read Article
jon.kay

Does Control of Inflammation Lower Cancer Risk?

Nov 23, 2021

Dr. Jonathan Kay's provocative video addresses whether the increased cancer risk associated with tofacitinib (Tofa) seen in the Pfizer Oral Surveillance (1133) study represents a real increased risk, an increased risk relative to a decreased risk with TNF inhibitors (TNFi) or an actual decreased

Read Article
ICYMI: Filgotinib (Jyseleca) was approved by European Commission approved for EU use in adults with moderately to severely active Ulcerative colitis (not responding to conventional therapy or a biologic). Rec based on Phase 2b/3 SELECTION trial. https://t.co/9VbCJse6Tr

Dr. John Cush @RheumNow( View Tweet )

Nov 21, 2021
RheumNow Podcast square

RheumNow Podcast - Unwillingness to Change Therapy (11.19.21)

Nov 19, 2021

Surely you’ve seen this or been plagued by this patient, one that is not doing well, in need of a new regimen; you outline it, timeline it, define the side effects and send them off with a new prescription.. But you later find out they did not change, did not fill the prescription.  Why were

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
Cush ACR learning computer online

Day 2 Report from ACR21

Nov 08, 2021

This report highlights the VITAL trial; the ORAL Surveillance Study; and the Microbiome study of monozygotic psoriasis patients.

Read Article
acr_session2.jpeg

Opening Day Report

Nov 06, 2021

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).



The Year in Review

Read Article
Gout.T2T.jpg

Treat-to-Target Works in Gout With No Cardiac Toxicity

ACR
Nov 04, 2021

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that allopurinol and febuxostat may effectively lower urate levels when used in a treat-to-target approach. Importantly, both urate-lowering therapies were very effective with 90% of

Read Article
exhibitor.floor.ACR

Industry Abstract Previews #ACR21 - Horizon, Aurinia, AstraZeneca

Nov 04, 2021

The pharmaceutical companies will feature the results of their pivotal clinical trials and data analyses at ACR Convergence 2021.  Below is a listing of some of their best studies for you to review and look for in the meeting. Often these become the pivotal studies for regulatory approval and

Read Article
test-214244__180.jpg (keep)

NOR-DRUM Study: TNF Inhibitor Therapeutic Drug Monitoring is Effective

ACR
Nov 03, 2021

New research presented this week at ACR  Convergence, the American College of  Rheumatology’s annual meeting, shows that proactive therapeutic drug monitoring, a newer treatment strategy where a patient’s drug serum levels are regularly assessed to adjust the dose and intervals, controlled 

Read Article
URI.infection.COrona.jpg

Infection Rates in Psoriatic Arthritis Patients on Biologics Have Decreased

ACR
Nov 03, 2021

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017.

Read Article
vaccine.jpg

Rituximab Patients May Benefit from Third COVID-19 Vaccine Dose

ACR
Nov 03, 2021

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving

Read Article
pssfing.jpg

Blacks with Systemic Sclerosis May Have More Severe Disease

ACR
Nov 02, 2021

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that Black people living with systemic sclerosis may have more severe disease and worse prognosis than patients in other racial or ethnic groups, and these worrying disparities may

Read Article
RA Hands Difficult deformity

JAK-pot Study: Cycling JAK Inhibitors Effective in Difficult-to-Treat RA

ACR
Nov 02, 2021

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with difficult-to-treat rheumatoid arthritis who do not have success with one Janus kinase inhibitor (JAK inhibitor) can achieve success either cycling to other JAKi

Read Article
vial.infusion.jpg (keep)

Ultra-Low Dose Rituximab Controls Disease Activity in RA

ACR
Nov 02, 2021

New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that in one study, the majority of rheumatoid arthritis patients on an ultra-low dose of the drug rituximab maintained low disease activity for up to four years, and rarely needed to

Read Article
guidelines.recommendations.jpg

Management of Immune-Related Adverse Events - ASCO Guideline

Nov 02, 2021

The American Society of Clinical Oncology, Inc (ASCO) has updated its guidelines and recommendations for the management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. Below are select statements from this guideline.

Read Article
DNA,genotyping,gene,sequencing

Large GWAS Study Reveals Genetic Basis for Osteoarthritis Phenotypes

Oct 29, 2021

Cell has published the results of a multinational, GWAS meta-analyses of 826,690 individuals that included 177,517 osteoarthritis patients, finding 52 previously unknown osteoarthritis (OA) genetic risk variants and linking OA genetic risks with joint distribution and pain-related

Read Article
ACR Applauds Bipartisan Letter Urging Congressional Action to Avoid Looming “Medicare Cliff” https://t.co/KXNHRdubZk

Dr. John Cush @RheumNow( View Tweet )

Oct 29, 2021
RheumNow Podcast square

RheumNow Podcast – Like Father, Like Daughter (10.29.2021)

Oct 29, 2021

Bad things happen when our patients go into the ICU and it's not always due to the disease. Good things happen when we rise from sitting. And guess what? Rheumatologists are setting cardiology straight about hydroxychloroquine and chloroquine. This, and a special recognition of parent-child

Read Article
PSO.Palmoplantar.jpg

Biologic Use and the Risk of Serious Infection in Psoriasis Patients

Oct 28, 2021

National Health Data from France examined biologic use in patients with moderate to severe psoriasis, and found the risk of serious infections (SIE) to be increased with some biologics (infliximab and adalimumab), but not others (etanercept, ustekinumab IL-17 and IL-23 inhibitors or

Read Article
lupus_0.jpg

BEAT-LUPUS: Sequential Belimumab After Rituximab in SLE

Oct 27, 2021

The Annals of Internal Medicine reports that targeting B-cells in refractory systemic lupus erythematosus (SLE) with sequential belimumab after rituximab may significantly reduce dsDNA antibody titers and lessen the number of future severe flares.

Read Article
×